Publications by authors named "Jef De Schutter"

Claim this Profile
F
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.
Ravit Geva, Loredana Vecchione, Konstantinos T Kalogeras, Benny Vittrup Jensen, Heinz-Josef Lenz, Jef De Schutter

Gut· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Zenia Saridaki, Joanne B Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter

Clin Cancer Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans

Lancet Oncol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.
Raphaël Maréchal, Jef De Schutter, Nathalie Nagy, Pieter Demetter, Arnaud Lemmers

BMC Cancer· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical biomarkers in oncology: focus on colorectal cancer.
Wendy De Roock, Bart Biesmans, Jef De Schutter, Sabine Tejpar

Mol Diagn Ther· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Bart Jacobs, Wendy De Roock, Hubert Piessevaux, Robin Van Oirbeek, Bart Biesmans, Jef De Schutter

J Clin Oncol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Hans Prenen, Jef De Schutter, Bart Jacobs, Wendy De Roock, Bart Biesmans

Clin Cancer Res· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter

Clin Cancer Res· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis